Escient Pharmaceuticals, Inc
6 clinical trials · Sponsor
◉ Watch Escient Pharmaceuticals, Inc
| Record | Firm | Date |
|---|---|---|
| An Open-Label Phase 1 Study in Healthy Male Subjects to Investigate the Absorption, Metabolism and Excretion of [14C]-EP262 Following Single-Dose Oral Administration (NCT06645704) | Escient Pharmaceuticals, Inc | 2024-10-01 |
| Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria (NCT06077773) | Escient Pharmaceuticals, Inc | 2023-09-25 |
| Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria (NCT06050928) | Escient Pharmaceuticals, Inc | 2023-08-30 |
| Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis (NCT05525520) | Escient Pharmaceuticals, Inc | 2022-10-06 |
| Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus (NCT04510090) | Escient Pharmaceuticals, Inc | 2020-09-07 |
Track Escient Pharmaceuticals, Inc automatically
Every clearance here is in the API, with alerts when new ones post.